| Code | CSB-RA013481MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Lu-AF87908, targeting microtubule-associated protein tau (MAPT). MAPT plays a critical role in stabilizing microtubules in neurons and regulating axonal transport. Under pathological conditions, MAPT undergoes abnormal hyperphosphorylation and aggregation, forming neurofibrillary tangles that are hallmark features of Alzheimer's disease and other tauopathies including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. The accumulation of pathological tau species correlates with neurodegeneration and cognitive decline, making MAPT a key therapeutic target in neurodegenerative disease research.
Lu-AF87908 is a clinical-stage therapeutic antibody developed to target extracellular tau species and prevent tau propagation between neurons. This biosimilar provides researchers with a valuable tool for investigating tau pathology mechanisms, studying cell-to-cell tau transmission, and exploring potential therapeutic interventions in tauopathy models. The antibody supports studies examining tau clearance pathways, aggregate formation, and neuroprotective strategies in neurodegenerative disease research.
There are currently no reviews for this product.